drugset / Trial / NCT06033612

Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults

NCT06033612 ↗

Phase 1 Completed 50 enrolled Pfizer
RandomizedSequentialQuadruple-blindTreatment

Summary

The main aims of the study are to assess the safety, tolerability, pharmacokinetics and food effects of RV299 compared to Placebo in healthy adult participants. The study consists of three parts: single ascending dose (Part A), multiple ascending doses (Part B) and food effect (Part C) in Caucasian participants.

Timeline

Start
2021-11-12
Primary completion
2022-07-27
Completion
2022-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule — Oral
Subject RV299 Unknown — Oral